Free Trial
NASDAQ:ERNA

Ernexa Therapeutics Q2 2025 Earnings Results & Report

Ernexa Therapeutics logo
$2.40 -0.09 (-3.61%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$2.35 -0.05 (-2.25%)
As of 10/9/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ernexa Therapeutics reported Q2 2025 earnings on August 13, 2025. The company reported EPS of -$15.25.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes

Ernexa Therapeutics EPS Results

Actual EPS
-$15.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ernexa Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Ernexa Therapeutics' next earnings date is estimated for Friday, November 6, 2026, based on past reporting schedules.

Conference Call Resources

Ernexa Therapeutics Q2 2025 Earnings FAQ

Ernexa Therapeutics (NASDAQ:ERNA) reported earnings of -$15.25 per share for Q2 2025. The report was announced on Wednesday, August 13, 2025.

Ernexa Therapeutics' next earnings date is estimated for Friday, November 6, 2026. MarketBeat tracks confirmed and estimated earnings dates for Ernexa Therapeutics on the company's earnings history page.

Ernexa Therapeutics Earnings Headlines

This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade. This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan.tc pixel
See More Ernexa Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ernexa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ernexa Therapeutics and other key companies, straight to your email.

About Ernexa Therapeutics

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

View Ernexa Therapeutics Profile